세계의 지질 나노입자 시장 예측(-2029년) : 제품별, LNP 유형별, 분자 유형별, 용도별, 최종사용자별, 서비스 유형별, 지역별

The global lipid nanoparticles market is expected to reach USD 350.5 million by 2029, from USD 271.8 million in 2024, at a CAGR of 5.2% from 2024 to 2029.

The global lipid nanoparticles services market is projected to reach USD 135.5 million in 2024 to USD 238.1 million in 2029, at a CAGR of 11.9% of during the forecast period of 2024 to 2029.

The growth of the lipid nanoparticles market has been significantly driven by the increasing use of lipid nanoparticles by players for the drug development of RNA therapeutics, personalized medicine, oncology & other therapies. Being a novel excipient for injectable therapies, limited regulatory approvals and resulting lack of established regulatory processes for lipid nanoparticle production are likely to deter the growth of the market.

" The Covid-19 commercial application segment was the highest share holding segment by application in 2023."

The commercial application segment under Covid-19 was the highest share holding segment in 2023 in the global lipid nanoparticles market. Lipid nanoparticles (LNP) usage in mRNA based COVID-19 vaccines due to their ability to enhance the stability and availability of mRNA was one of the drivers for establishing this market. With the decline in COVID-19 vaccinations, it is expected that clinical applications such as development of RNA therapeutics & LNP based drugs for oncology and other indications will drive the growth in this market.

"The US has continued to dominate the lipid nanoparticles market during the forecast period of 2024-2029."

Two main mRNA-based COVID-19 vaccine producers that have shown success are Pfizer-BioNTech and Moderna, who have generated billions of doses together. With US government initiative such as Operation Warp Speed, US based biopharmaceutical companies have developed signicant capacities for RNA & LNP production as well as capabilities for development of LNP based drugs. Established LNP & RNA ecosystem and drug development activities from pharmaceutical & biotech companies as well as CDMOs are expected to help the US market retain its leadership in lipid nanoparticles development & manufacturing.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

List of Companies Profiled in the Report:

Avanti Polar Lipids (Croda International plc) (US)

Merck KGaA (Germany)

Evonik Industries AG (Germany)

IOI Oleo Gmbh (Germany)

FUJIFILM Pharmaceuticals U.S.A., Inc. (US)

Nippon Fine Chemical (Japan)

Recipharm AB (Sweden)

Emergent (US)

EUROAPI (France)

Cayman Chemical (US)

CordenPharma (Switzerland)

NOF CORPOTATION (Japan)

Precision NanoSystems (Canada)

Gattefosse (France)

Acuitas Therapeutics (Canada)

Creative Biolabs (US)

Curapath (Spain)

Lipoid Gmbh (Germany)

Nanocs, Inc. (US)

MedKoo Biosciences, Inc. (US)

Polysciences, Inc. (US)

BIOVECTRA (Canada)

Ascendia Pharmaceuticals (US)

Curia Global, Inc. (US)

Vernal Biosciences (US)

Research Coverage:

This research report categorizes the lipid nanoparticles market by product (ionizable lipids, PEGylated lipids, neutral lipids, phospholipids, kits & reagents, and other formulation materials), by LNP type (solid lipid nanoparticles, nanostructured lipid carriers, and other types), by molecule type (si RNA, m RNA, and other molecules), by application ((commercial (Polyneuropathy, Covid-19), clinical (Covid-19, cancer, other diseases)), by end user (pharmaceutical & biotechnologies companies, CDMO's, academic & research institutes), by service type (formulation development services, manufacturing services, and other services), by end user of services (pharmaceutical & biotechnologies companies, academic & research institutes), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the lipid nanoparticles market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, services, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the lipid nanoparticles market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall lipid nanoparticles market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (Increasing use of lipid nanoparticles in anti-cancer therapies, Increasing use of lipid nanoparticles in RNA-based therapies, Growing government focus on R&D of key players for the development of lipid nanoparticles-based drugs, restraints (Stringent regulations associated lipid nanoparticles, High cost and difficulties for production of lipid nanoparticles), opportunities (Growing demand for advanced drug delivery systems), and Challenges (Formulation related challenges).
• Product Development/Innovation: Detailed insights on newly launched products/services of the lipid nanoparticles market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, new services, untapped geographies, recent developments, and investments in the lipid nanoparticles market
• Competitive Assessment: Avanti Polar Lipids (Croda International plc) (US), Merck KGaA (Germany), Evonik Industries AG (Germany), FUJIFILM Pharmaceuticals U.S.A., Inc. (US), Nippon Fine Chemical (Japan), Recipharm AB (Sweden), Emergent (US), EUROAPI (France), Cayman Chemical (US), CordenPharma (Switzerland), NOF CORPORATION (Japan), IOI Oleo GmbH (Germany), among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
• 1.4 YEARS CONSIDERED
• 1.5 CURRENCY CONSIDERED
  • 1.5.1 VALUE UNIT
• 1.6 MARKET STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 GLOBAL MARKET ESTIMATION
  • 2.2.2 INSIGHTS OF PRIMARY EXPERTS
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 LNP RAW MATERIALS & SERVICES MARKET OVERVIEW
• 4.2 ASIA PACIFIC: LNP RAW MATERIALS & SERVICES MARKET, BY PRODUCT
• 4.3 LNP RAW MATERIALS & SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 LNP RAW MATERIALS MARKET, BY END USER, 2023
• 4.5 LNP SERVICES MARKET, BY END USER, 2023

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing use of lipid nanoparticles in anti-cancer research
    • 5.2.1.2 High uptake in RNA-based therapeutic research
    • 5.2.1.3 Growing government focus on R&D for LNP-based drugs
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Stringent regulatory requirements
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing demand for advanced drug delivery systems
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Challenges associated with LNP formulation
  • 5.2.5 INDUSTRY TRENDS
    • 5.2.5.1 Growing preference for personalized medicine and targeted drug delivery
    • 5.2.5.2 Advancements in mRNA-based vaccine technology
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 PRICING ANALYSIS
  • 5.4.1 INDICATIVE SELLING PRICE OF LNP PRODUCTS, BY KEY PLAYER
  • 5.4.2 INDICATIVE SELLING PRICE, BY PRODUCT
• 5.5 SUPPLY CHAIN ANALYSIS
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
  • 5.7.1 LNP RAW MATERIALS & SERVICES MARKET: ROLE IN ECOSYSTEM
• 5.8 TECHNOLOGY ANALYSIS
  • 5.8.1 KEY TECHNOLOGIES
    • 5.8.1.1 Nanotechnology-based drug delivery
    • 5.8.1.2 Nucleic acid delivery
  • 5.8.2 COMPLEMENTARY TECHNOLOGIES
    • 5.8.2.1 Drug encapsulation techniques
    • 5.8.2.2 Surface modification and functionalization technologies
  • 5.8.3 ADJACENT TECHNOLOGIES
    • 5.8.3.1 Biotechnology & genetic engineering technologies
    • 5.8.3.2 Nanotechnology-based formulation techniques
• 5.9 PATENT ANALYSIS
  • 5.9.1 PATENTS FILED, BY DOCUMENT TYPE, 2014-2023
  • 5.9.2 INNOVATION AND PATENT APPLICATIONS
  • 5.9.3 TOP APPLICANTS
• 5.10 KEY CONFERENCES & EVENTS, 2024-2025
• 5.11 REGULATORY LANDSCAPE
  • 5.11.1 REGULATORY SCENARIO
  • 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.12 PORTER'S FIVE FORCES ANALYSIS
  • 5.12.1 DEGREE OF COMPETITION
  • 5.12.2 BARGAINING POWER OF SUPPLIERS
  • 5.12.3 BARGAINING POWER OF BUYERS
  • 5.12.4 THREAT OF SUBSTITUTES
  • 5.12.5 THREAT OF NEW ENTRANTS
• 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.13.1 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR LIPID NANOPARTICLES: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
• 5.14 KEY BUYING CRITERIA
  • 5.14.1 BUYING CRITERIA FOR LNP RAW MATERIALS
  • 5.14.2 BUYING CRITERIA FOR LNP RAW MATERIALS, BY END USER
  • 5.14.3 BUYING CRITERIA FOR LNP SERVICES
  • 5.14.4 BUYING CRITERIA FOR LNP SERVICES, BY END USER
• 5.15 INVESTMENT & FUNDING SCENARIO
• 5.16 IMPACT OF GENERATIVE AI ON LNP RAW MATERIALS & SERVICES MARKET

6 LNP RAW MATERIALS MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 IONIZABLE LIPIDS
  • 6.2.1 HIGH DEMAND FOR MRNA-BASED VACCINES TO PROPEL MARKET
• 6.3 PEGYLATED LIPIDS
  • 6.3.1 GROWING FOCUS ON NUCLEIC ACID MEDICINES TO BOOST DEMAND
• 6.4 NEUTRAL LIPIDS
  • 6.4.1 ENHANCED STABILITY AND HIGH UPTAKE IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET
• 6.5 PHOSPHOLIPIDS
  • 6.5.1 BIOLOGICAL COMPATIBILITY AND CUSTOMIZATION FEATURES TO SUPPORT MARKET GROWTH
• 6.6 KITS & REAGENTS
  • 6.6.1 ADVANCEMENTS IN LNP FORMULATION TECHNIQUES TO DRIVE MARKET
• 6.7 OTHER FORMULATION MATERIALS

7 LNP RAW MATERIALS MARKET, BY LNP TYPE

• 7.1 INTRODUCTION
• 7.2 SOLID LIPID NANOPARTICLES (SLNS)
  • 7.2.1 ADVANTAGES OVER CONVENTIONAL DRUG CARRIERS TO DRIVE MARKET
• 7.3 NANOSTRUCTURED LIPID CARRIERS (NLCS)
  • 7.3.1 HIGH DRUG LOADING CAPACITY TO PROPEL MARKET
• 7.4 OTHER LNP TYPES

8 LNP RAW MATERIALS MARKET, BY MOLECULE TYPE

• 8.1 INTRODUCTION
• 8.2 SIRNA
  • 8.2.1 GROWING FOCUS ON TARGETED DRUG DELIVERY TO DRIVE MARKET
• 8.3 MRNA
  • 8.3.1 GROWING UPTAKE IN VACCINE DEVELOPMENT TO PROPEL MARKET
• 8.4 OTHER MOLECULES

9 LNP RAW MATERIALS MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 COMMERCIAL APPLICATIONS
  • 9.2.1 POLYNEUROPATHY
    • 9.2.1.1 Ability to provide targeted & sustained release of therapeutic agents to boost demand
  • 9.2.2 COVID-19
    • 9.2.2.1 Enhanced stability and distribution of mRNA to drive market
• 9.3 CLINICAL APPLICATIONS
  • 9.3.1 COVID-19
    • 9.3.1.1 Threat of evolving emerging variants to fuel uptake
  • 9.3.2 CANCER
    • 9.3.2.1 Increasing focus on oncology therapeutics to drive market
  • 9.3.3 OTHER CLINICAL APPLICATIONS

10 LNP RAW MATERIALS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 10.2.1 INCREASING DRUG DEVELOPMENT ACTIVITIES TO FUEL MARKET
• 10.3 ACADEMIC & RESEARCH INSTITUTES
  • 10.3.1 HIGH FOCUS ON R&D FOR GENE THERAPY AND MEDICATION ADMINISTRATION TO DRIVE MARKET
• 10.4 CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS (CDMOS)
  • 10.4.1 GROWING OUTSOURCING OF LNP FORMULATION SERVICES TO PROPEL MARKET

11 LNP SERVICES MARKET, BY SERVICE TYPE

• 11.1 INTRODUCTION
• 11.2 FORMULATION DEVELOPMENT SERVICES
  • 11.2.1 GROWING FOCUS ON TARGETED & EFFECTIVE DRUG DELIVERY TO PROPEL MARKET
• 11.3 MANUFACTURING SERVICES
  • 11.3.1 RISING DEMAND FOR LIPID-BASED CARRIERS FOR GENE THERAPY AND VACCINE DEVELOPMENT TO DRIVE MARKET
• 11.4 OTHER SERVICES

12 LNP SERVICES MARKET, BY END USER

• 12.1 INTRODUCTION
• 12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 12.2.1 DRUG DEVELOPMENT & COMMERCIALIZATION TO PROPEL MARKET
• 12.3 ACADEMIC & RESEARCH INSTITUTES
  • 12.3.1 ACCESS TO ADVANCED INFRASTRUCTURE AND SPECIALIZED EXPERTISE TO SUPPORT MARKET GROWTH

13 LNP RAW MATERIALS & SERVICES MARKET, BY REGION

• 13.1 INTRODUCTION
• 13.2 NORTH AMERICA
  • 13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 13.2.2 US
    • 13.2.2.1 High pharmaceutical R&D expenditure to drive market
  • 13.2.3 CANADA
    • 13.2.3.1 Growing focus on personalized medicine to drive market
• 13.3 EUROPE
  • 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 13.3.2 GERMANY
    • 13.3.2.1 Rising development activities for LNP production to drive market
  • 13.3.3 UK
    • 13.3.3.1 Pioneering research programs for drug delivery systems to boost demand
  • 13.3.4 FRANCE
    • 13.3.4.1 Government funding for proteomics and genomics research to support market growth
  • 13.3.5 ITALY
    • 13.3.5.1 Growth in life sciences research to propel market
  • 13.3.6 SPAIN
    • 13.3.6.1 Growing demand for cancer therapeutics to drive market
  • 13.3.7 REST OF EUROPE
• 13.4 ASIA PACIFIC
  • 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 13.4.2 CHINA
    • 13.4.2.1 Low manufacturing costs and rising outsourcing of services to CDMOs to drive market
  • 13.4.3 JAPAN
    • 13.4.3.1 Demand for LNP-based mRNA vaccines to fuel market
  • 13.4.4 INDIA
    • 13.4.4.1 Growth in pharmaceutical industry to drive market
  • 13.4.5 SOUTH KOREA
    • 13.4.5.1 Rising number of clinical trials to boost demand
  • 13.4.6 AUSTRALIA
    • 13.4.6.1 Growing requirement for innovative drug delivery systems to propel market
  • 13.4.7 REST OF ASIA PACIFIC
• 13.5 LATIN AMERICA
  • 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 13.5.2 BRAZIL
    • 13.5.2.1 Global manufacturing hub for pharmaceutical drugs to fuel uptake
  • 13.5.3 MEXICO
    • 13.5.3.1 Large target patient population and demand for novel drug delivery technology to drive market
  • 13.5.4 REST OF LATIN AMERICA
• 13.6 MIDDLE EAST
  • 13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 13.6.2 GCC COUNTRIES
    • 13.6.2.1 Economic & healthcare expansion to support market growth
  • 13.6.3 REST OF MIDDLE EAST
• 13.7 AFRICA
  • 13.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
  • 13.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

14 COMPETITIVE LANDSCAPE

• 14.1 INTRODUCTION
• 14.2 KEY PLAYER STRATEGY/RIGHT TO WIN
• 14.3 REVENUE ANALYSIS
• 14.4 MARKET SHARE ANALYSIS
  • 14.4.1 LNP SERVICES MARKET
• 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 14.5.1 STARS
  • 14.5.2 EMERGING LEADERS
  • 14.5.3 PERVASIVE PLAYERS
  • 14.5.4 PARTICIPANTS
  • 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 14.5.5.1 Company footprint
    • 14.5.5.2 Product footprint
    • 14.5.5.3 Application footprint
    • 14.5.5.4 Service type footprint
    • 14.5.5.5 Region footprint
• 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 14.6.1 PROGRESSIVE COMPANIES
  • 14.6.2 RESPONSIVE COMPANIES
  • 14.6.3 DYNAMIC COMPANIES
  • 14.6.4 STARTING BLOCKS
  • 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 14.7 COMPANY VALUATION & FINANCIAL METRICS
  • 14.7.1 FINANCIAL METRICS
  • 14.7.2 COMPANY VALUATION
• 14.8 BRAND/PRODUCT COMPARISON ANALYSIS
• 14.9 COMPETITIVE SCENARIO
  • 14.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
  • 14.9.2 DEALS
  • 14.9.3 EXPANSIONS

15 COMPANY PROFILES

• 15.1 KEY PLAYERS
  • 15.1.1 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC)
    • 15.1.1.1 Business overview
    • 15.1.1.2 Products/Services offered
    • 15.1.1.3 Recent developments
      • 15.1.1.3.1 Deals
    • 15.1.1.4 MnM view
      • 15.1.1.4.1 Key strengths
      • 15.1.1.4.2 Strategic choices
      • 15.1.1.4.3 Weaknesses & competitive threats
  • 15.1.2 MERCK KGAA
    • 15.1.2.1 Business overview
    • 15.1.2.2 Products/Services offered
    • 15.1.2.3 Recent developments
      • 15.1.2.3.1 Deals
      • 15.1.2.3.2 Expansions
    • 15.1.2.4 MnM view
      • 15.1.2.4.1 Key strengths
      • 15.1.2.4.2 Strategic choices
      • 15.1.2.4.3 Weaknesses & competitive threats
  • 15.1.3 EVONIK INDUSTRIES AG
    • 15.1.3.1 Business overview
    • 15.1.3.2 Products/Services offered
    • 15.1.3.3 Recent developments
      • 15.1.3.3.1 Deals
    • 15.1.3.4 MnM view
      • 15.1.3.4.1 Key strengths
      • 15.1.3.4.2 Strategic choices
      • 15.1.3.4.3 Weaknesses & competitive threats
  • 15.1.4 NIPPON FINE CHEMICAL
    • 15.1.4.1 Business overview
    • 15.1.4.2 Products/Services offered
    • 15.1.4.3 MnM view
      • 15.1.4.3.1 Key strengths
      • 15.1.4.3.2 Strategic choices
      • 15.1.4.3.3 Weaknesses & competitive threats
  • 15.1.5 NOF CORPORATION
    • 15.1.5.1 Business overview
    • 15.1.5.2 Products/Services offered
    • 15.1.5.3 Recent developments
      • 15.1.5.3.1 Deals
    • 15.1.5.4 MnM view
      • 15.1.5.4.1 Key strengths
      • 15.1.5.4.2 Strategic choices
      • 15.1.5.4.3 Weaknesses & competitive threats
  • 15.1.6 FUJIFILM PHARMACEUTICALS U.S.A., INC. (FUJIFILM HOLDINGS CORPORATION)
    • 15.1.6.1 Business overview
    • 15.1.6.2 Products/Services offered
    • 15.1.6.3 Recent developments
      • 15.1.6.3.1 Expansions
  • 15.1.7 PRECISION NANOSYSTEMS (CYTIVA)
    • 15.1.7.1 Business overview
    • 15.1.7.2 Products/Services offered
    • 15.1.7.3 Recent developments
      • 15.1.7.3.1 Product/Service launches
      • 15.1.7.3.2 Deals
      • 15.1.7.3.3 Expansions
  • 15.1.8 RECIPHARM AB
    • 15.1.8.1 Business overview
    • 15.1.8.2 Products/Services offered
    • 15.1.8.3 Recent developments
      • 15.1.8.3.1 Deals
  • 15.1.9 EMERGENT
    • 15.1.9.1 Business overview
    • 15.1.9.2 Products/Services offered
    • 15.1.9.3 Recent developments
      • 15.1.9.3.1 Deals
  • 15.1.10 EUROAPI
    • 15.1.10.1 Business overview
    • 15.1.10.2 Products/Services offered
  • 15.1.11 CAYMAN CHEMICAL
    • 15.1.11.1 Business overview
    • 15.1.11.2 Products/Services offered
  • 15.1.12 CORDENPHARMA
    • 15.1.12.1 Business overview
    • 15.1.12.2 Products/Services offered
    • 15.1.12.3 Recent developments
      • 15.1.12.3.1 Product/Service launches
      • 15.1.12.3.2 Deals
      • 15.1.12.3.3 Expansions
  • 15.1.13 GATTEFOSSE
    • 15.1.13.1 Business overview
    • 15.1.13.2 Products/Services offered
  • 15.1.14 ACUITAS THERAPEUTICS
    • 15.1.14.1 Business overview
    • 15.1.14.2 Products/Services offered
    • 15.1.14.3 Recent developments
      • 15.1.14.3.1 Deals
  • 15.1.15 IOI OLEO GMBH
    • 15.1.15.1 Business overview
    • 15.1.15.2 Products/Services offered
• 15.2 OTHER PLAYERS
  • 15.2.1 CREATIVE BIOLABS
  • 15.2.2 CURAPATH
  • 15.2.3 LIPOID GMBH
  • 15.2.4 NANOCS INC.
  • 15.2.5 MEDKOO BIOSCIENCES, INC.
  • 15.2.6 POLYSCIENCES INC.
  • 15.2.7 BIOVECTRA
  • 15.2.8 ASCENDIA PHARMACEUTICALS
  • 15.2.9 CURIA GLOBAL, INC.
  • 15.2.10 VERNAL BIOSCIENCES

16 APPENDIX

• 16.1 DISCUSSION GUIDE
• 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 16.3 CUSTOMIZATION OPTIONS
• 16.4 RELATED REPORTS
• 16.5 AUTHOR DETAILS